Biotage, Uppsala, Sweden, has launched Isolute Hydro dual mode extraction (DME)+ fixed well plates and columns for the efficient removal of matrix components from urine, using a simple pass-through workflow. The company’s novel, patent-pending DME methodology was developed to provide more-effective removal of such matrix components as creatinine, pigments, residual hydrolysis enzymes, salts, and urea from urine, using a combination of liquid partitioning and scavenging modes. Compared to the dilute-and-shoot approach, analyte sensitivity is increased, and instrument sensitivity is maintained over multiple injections, improving assay robustness and reducing costly downtime. The inclusion of Biotage Hydro frit technology means that urine samples can be hydrolyzed in situ in the well or column, eliminating the need for a post-hydrolysis sample transfer step. Specimens can be processed using 96-well compatible automated sample extraction systems, positive pressure manifolds, and vacuum manifolds. Raw urine specimens of up to 200 µL can be cleaned up using the 400 mg 96-well plate and column formats. For more information, visit Biotage.